PDS merger with Edge Therapeutics update

RNS Number : 2254T

NetScientific PLC

19 March 2019

 

NetScientific plc

("NetScientific" or the "Company")

PDS merger with Edge Therapeutics update

Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation ("PDS"), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of $10 values NetScientific's holding in PDS at £4,081,451*. It is the Company's intention to hold the shares and to make a decision on its position in due course.

*Using a US:GBP exchange rate of 1.33

#  #  #

For more information, please contact:

NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO	Tel: [phone]
WH Ireland Limited (NOMAD, Financial Adviser and Broker) Chris Fielding / Jessica Cave	Tel: [phone]
Consilium Strategic Communications             Mary-Jane Elliott / Chris Welsh / Laura Thornton [e-mail]	Tel: [phone]

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

 

END

 

 

MSCKMGMFMRFGLZZ